Tufts CSDD Impact Reports summarize current original research from Tufts CSDD and present it in a concise, easy-to-read format. This bi-monthly publication – the only one of its kind – presents data, analyses, and insights on critical drug development and regulatory issues.

Industry decision makers from pharma, biotech, CROs and niche provider companies use Tufts CSDD Impact Reports to keep informed – and to shape R&D, manufacturing, marketing, sales, and strategic planning decisions.

Timely topics recently covered in Tufts CSDD Impact Reports include:

• Cost to develop new biotech products
• Fastest drug developers enjoy revenue gains and cost savings
• Approval times for new drugs under PDUFA
• Recent developments in R&D analysis of EU biopharmaceutical reviews
• An analysis of FDA request for postmarketing studies
• The changing investigative site landscape
• FDA’s response to U.S. pediatric studies incentive

What professionals around the world say about Tufts CSDD Impact Reports

Subscribers also receive the Tufts CSDD Outlook Report, published in January, which highlights near-term pharmaceutical and biopharmaceutical drug development trends.

Subscription available in hard copy format or online in PDF format.

View Sample Issue

Annual Subscription for Six Bi-monthly Issues
$480 regular annual subscription rate ($545 outside the USA)
$240 special rate, limited to government, academic, and non-profit organizations ($345 outside the USA)

Click here to start your annual subscription.

Corporate Multi-Reader Subscriptions
Click here for more information about corporate multi-reader subscriptions.

Single Issue Rate: $125
Click here to order

To Renew
Click here to renew your subscription

To view samples, subscription, and single issue order forms, please download Adobe Acrobat Reader to your PC free of charge at: http://www.adobe.com/products/acrobat/readstep2.html.

Recent Tufts CSDD Impact Report single issues:

May/June 2009, Vol. 11, No. 3
Therapeutic peptides in clinical study in 2000–07 nearly doubled 1990s rate
View summary    Purchase single issue

March/April 2009, Vol. 11, No. 2
75% of U.S. health plans reimburse
off–label uses of prescription drugs
View summary    Purchase single issue

January/February 2009, vol.11, no.1
Current investigator landscape poses a growing challenge for sponsors
View summary    Purchase single issue

November/December 2008, Vol.10, No.6
While total approvals decline, U.S. is
preferred market for first launch
View summary    Purchase single issue

September/October 2008, Vol.10, No.5
Fast track designations more than
doubled during the last five years
View summary    Purchase single issue

July/August 2008 Vol.10 No.4
Postmarketing studies are becoming
the norm in U.S., Europe, and Japan
View summary    Purchase single issue

May/June 2008, vol.10, no.3
Drug plans non–compliant with Medicare
View summary    Purchase single issue

March/April 2008, vol.10, no.2
Number of mAbs entering clinical
study nearly tripled in last decade

View summary    Purchase single issue

January/February 2008, vol.10, no.1
Growing protocol design complexity
stresses investigators, volunteers
View summary    Purchase single issue

2007 (click here to preview issues and summaries)

2006 (click here to preview issues and summaries)

2005 (click here to preview issues and summaries)

2004 (click here to preview issues and summaries)

2003 (click here to preview issues and summaries)

2002 (click here to preview issues and summaries)

2001 (click here to preview issues and summaries)

2000 (click here to preview issues and summaries)

1999 (click here to preview issues and summaries)